Owner Scorecard


← All companies ← URG Manual URI → ← UPB Pharmaceuticals USNA →

URGN, UroGen Pharma Ltd.

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.

We have developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based technology that has the potential to improve therapeutic profiles of existing drugs.

Our technology is designed to enable longer exposure of urinary tract tissue to medications, making local therapy a potentially more effective treatment option.

Latest annual: FY2025 10-K
URGN · UroGen Pharma Ltd.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$110M
+21.4% YoY · 56% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $189M 5-yr avg $79M
Operating margin −35.3% 5-yr avg −123.0%
Owner-earnings margin −84% 5-yr avg −133%
Free cash flow margin −84% 5-yr avg −133%

Next report Est. 11/2–11/9 · the 10-Q for the quarter ended late September · due within 45 days of period end · has filed ~37 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
Operating margin has run around −114% through the cycle on a 90% gross margin, the operating line in the red even at its best — so the lever is whether the spending below the gross line can come down enough to clear a profit: revenue growth against the cost curve, and the cash runway until it does. Stock-based pay runs about 16% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −58%, above 15% in 0 of 4 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$18M$8M$1M$18K$12M$48M$64M$83M$90M$110M$189MRevenueRevenue
$18M$8M($675K)$18K$11M$43M$57M$73M$82M$97M$171MGross profitGross prof.
100%93%−60%100%91%89%88%89%90%89%91%Gross marginGross mgn
37%108%n/mn/m765%182%129%113%134%141%94%SG&A / revenueSG&A/rev
229%n/mn/m401%99%82%55%63%61%32%R&D / revenueR&D/rev
$798K($20M)($77M)($109M)($127M)($92M)($79M)($66M)($97M)($125M)($67M)Operating incomeOp. inc.
4.6%−244.5%n/mn/mn/m−192.1%−122.8%−79.2%−107.1%−113.7%−35.3%Operating marginOp. mgn
($2M)($20M)($76M)($105M)($125M)($109M)($108M)($98M)($124M)($153M)Pretax incomePretax
($2M)($20M)($76M)($105M)($128M)($111M)($110M)($102M)($127M)($153M)($98M)Net incomeNet inc.
Cash flow & returns
$4M($10M)($37M)($71M)($106M)($85M)($88M)($76M)($97M)($162M)($159M)Operating cash flowOp. cash
$200K$200K$400K$300K$416K$831K$924K$802K$329K$307K$308KDepreciation & amortizationD&A
$4M$4M$7M$4M($6M)$2M$11M$16M$17M($21M)($78M)Working capital & otherWC & other
$695K$271K$560K$325K$1M$752K$254K$194K$295K$289K$218KCapexCapex
4.0%3.3%49.6%n/m10.3%1.6%0.4%0.2%0.3%0.3%0.1%Capex / revenueCapex/rev
$4M($10M)($38M)($71M)($106M)($86M)($88M)($77M)($97M)($163M)($159M)Owner earningsOwner earn.
22.8%−119.7%n/mn/m−900.9%−178.3%−136.4%−92.6%−107.4%−148.2%−84.3%Owner earnings marginOE mgn
$3M($10M)($38M)($71M)($107M)($86M)($88M)($77M)($97M)($163M)($159M)Free cash flowFCF
19.9%−120.6%n/mn/m−907.7%−178.3%−136.4%−92.6%−107.4%−148.2%−84.3%Free cash flow marginFCF mgn
($719K)($36M)$35M($146M)$93M$4M$1M($953K)($21M)$62MInvesting cash flowInv. cash
($9K)$62M$66M$165M$17M$72M$97M$117M$195M$40MFinancing cash flowFin. cash
$3M$16M$64M($51M)$4M($9M)$11M$40M$77M($61M)Change in cashΔ cash
4%-50%-66%-230%ROICROIC
-12%-29%-84%-58%-133%-1317%Return on equityROE
−12%−29%−84%−58%−133%n/mRetained to equityRetained/eq
Balance sheet
$73M$101M$50M$53M$44M$55M$151M$283M$160M$109MCash & investmentsCash+inv
$7M$12M$13M$15M$20M$33M$89MReceivablesReceiv.
$316K$2M$5M$4M$6M$9M$16M$25MInventoryInvent.
$3M$4M$5M$3M$6M$6M$7M$11M$12M$15MAccounts payablePayables
($3M)$6M$11M$12M$15M$19M$37M$98MOperating working capitalOper. WC
$74M$102M$149M$116M$114M$129M$169M$276M$186M$235MCurrent assetsCur. assets
$7M$13M$19M$21M$22M$24M$31M$46M$46M$62MCurrent liabilitiesCur. liab.
10.6×7.6×7.6×5.4×5.1×5.4×5.4×6.0×4.0×3.8×Current ratioCurr. ratio
$805K$948K$977K$2M$2M$1M$689K$655K$637KNet PP&ENet PP&E
$76M$104M$202M$122M$120M$136M$178M$286M$200M$253MTotal assetsAssets
$0$98M$99M$122M$122M$189MTotal debtDebt
($44M)$42M($53M)($161M)($38M)$79MNet debt / (cash)Net debt
$7M$13M$22M$26M$111M$225M$244M$295M$306MTotal liabilitiesTotal liab.
$16M$69M$90M$180M$96M$8M($89M)($65M)($9M)($105M)($132M)Shareholders’ equityEquity
11.2%77.2%n/mn/m237.5%48.1%16.4%11.3%14.5%10.9%8.5%Stock comp / revenueSBC/rev
Per share
2.3M9.7M15.8M20.5M21.8M22.3M22.8M28.8M42.9M48.1M50.3MShares out (basic avg)Shares
$7.60$0.84$0.07$0.00$0.54$2.15$2.82$2.87$2.11$2.28$3.75Revenue / shareRev/sh
$-0.84$-2.06$-4.80$-5.12$-5.90$-4.96$-4.81$-3.55$-2.96$-3.19$-1.94EPS (basic)EPS
$1.73$-1.01$-2.40$-3.48$-4.88$-3.83$-3.85$-2.66$-2.26$-3.38$-3.16Owner earnings / shareOE/sh
$1.52$-1.01$-2.41$-3.48$-4.92$-3.83$-3.85$-2.66$-2.26$-3.38$-3.16Free cash flow / shareFCF/sh
$0.30$0.03$0.04$0.02$0.06$0.03$0.01$0.01$0.01$0.01$0.00Cap. spending / shareCapex/sh
$7.07$7.05$5.72$8.78$4.42$0.38$-3.92$-2.26$-0.21$-2.19$-2.63Book value / shareBVPS

The diluted share count moved ×4.21 into 2017 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.62 into 2018 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.49 into 2024 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share−12.5%/yr+33.3%/yr
Capital spending / share−35.3%/yr−36.0%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported a $153M loss but ($163M) of owner earnings: $9M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023FY2022FY2021
Reported net income($153M)($127M)($102M)($110M)($111M)
Depreciation & amortizationnon-cash charge added back+$307K+$329K+$802K+$924K+$831K
Stock-based compensationreal costnon-cash, but a real cost+$12M+$13M+$9M+$11M+$23M
Working capital & othertiming of cash in and out, other non-cash items−$21M+$17M+$16M+$11M+$2M
Cash from operations($162M)($97M)($76M)($88M)($85M)
Capital expenditurecash put back in to keep running and to grow−$289K−$295K−$194K−$254K−$752K
Owner earnings($163M)($97M)($77M)($88M)($86M)
Owner-earnings marginowner earnings ÷ revenue-148%-107%-93%-136%-178%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $12M), owner earnings is nearer ($175M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • No meaningful interest burden
    Little or no interest expense reported
    What this means

    Little or no interest expense reported, the business isn't leaning on lenders to operate.

  • Net cash
    Cash $111M + ST investments $49M − debt $122M
    What this means

    Cash and short-term investments exceed every dollar of debt by $38M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 110 + DIO 483 − DPO 356 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not meaningful here
    Invested capital ($94M) = debt $122M + equity ($105M) − cash
    Industry peers: median -38%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    7-yr median margin, range -178%–23%; latest ($163M) = operating cash ($162M) − maintenance capex $289K
    Industry peers: median -123%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -148% of revenue this year, a -120% median across 7 years. Treating stock comp as the real expense it is (less $12M of SBC) leaves ($175M).

  • Loss, and burning cash
    Net income ($153M) · cash from operations ($162M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.94×
    Maintaining
    Capex $289K ÷ depreciation & amortization as filed $307K
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 10.9%
    Stock pay, share count unread
    Stock compensation $12M (fiscal 2025), 10.9% of revenue · no repurchases · the share count is not comparable across these years (a split or a first listing sits in the record), so the drift is withheld
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $110M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 4.01×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $122M vs $140M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 10 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-2.61/share (latest year $-3.14), the averaged base the calculator's gate runs on, and book value is $-2.16/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 10
    What this means

    Lost money in 10 year(s), look at what happened there before trusting the average.

  • Operating margin −2361% → −100% (3-yr avg ends)

    In the filing’s words The record and the words agree: the margin widened and the filing attributes the gain to its own pricing, not volume alone.

    What this means

    Through the cycle the operating margin widened — about −2361% early to −100% lately, median −192% — pricing power intact or improving.

  • Worst year 2019 · −608211.1% op. margin
    What this means

    Operations went underwater in 2019, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$235M
  • Cash & short-term investments$109M
  • Receivables$89M
  • Inventory$25M
  • Other current assets$13M
Current liabilities$62M
  • Accounts payable$15M
  • Other current liabilities$46M
Current ratio3.80×all current assets ÷ what's due · Graham looked for 2×
Quick ratio3.41×stricter: inventory excluded
Cash ratio1.77×strictest: cash alone against what's due
Working capital$174Mthe cushion left after near-term bills
Cash runway0.7 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+199.2%the freshest read on whether the business is still growing
Current ratio, recent quarters9.0× → 3.8×
Deeper floors
Tangible book value($132M)equity stripped of goodwill & intangibles
Net current asset value($150M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$192M$3M of it operating leases

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2023Elizabeth Barrett$4.6M$6.3M($77M)
2024Elizabeth Barrett$4.1M$1.9M($97M)
2025Elizabeth Barrett$4.3M$11.8M($163M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership4.8%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$12M

    The slice of the business handed to employees in shares in fiscal 2025, 10.9% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Income taxes, Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
XNCRXencor Inc.$126M-69.2%-12%-34%
GYREGyre Therapeutics Inc.$117M96%4y-25.1%-9%-0%
OGIOrganigram Global Inc.$116M-1%-26.0%-9%-42%
URGNUroGen Pharma Ltd.$110M-60%1y-113.7%-58%4y-120%
TBPHTheravance Biopharma Inc.$107M61%1y-343.1%-73%-208%
ZVRAZevra Therapeutics Inc.$106M22%1y-158.4%-127%-123%
ZYMEZymeworks Inc.$106M-180.7%-38%-153%
SPRYARS Pharmaceuticals Inc.$84M-212.9%-39%-203%
Group median22%-136.1%-38%-121%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

UroGen Pharma Ltd. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered46%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−84%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "UroGen Pharma Ltd. (URGN), the owner's record," https://ownerscorecard.com/c/URGN, data as of 2026-08-17.

Manual order: ← URG its page in the Manual URI →

Industry order: ← UPB the Pharmaceuticals chapter USNA →